(Q36671063)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

title

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

main subject

phase I clinical trial

0 references

author

Adrian Harris

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

author name string

C Han

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

J P Braybrooke

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

G Deplanque

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

M Taylor

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

D Mackintosh

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

K Kaur

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

K Samouri

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

T S Ganesan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

D C Talbot

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

language of work or name

English

0 references

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

19 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

1166-1171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601218

19 December 2019

exact match

0 references

cites work

A phase 1 study of tazarotene in adults with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Reporting results of cancer treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Responses and toxic deaths in phase I clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Perceptions of cancer patients and their physicians involved in phase I trials

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394292

Therapeutic response in phase I trials of antineoplastic agents

20 September 2018

1 reference

12 December 2020

Response rates, duration of response, and dose response effects in phase I studies of antineoplastics

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

Prognostic factors for survival in patients treated in phase I clinical trials

1 reference

12 December 2020

Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology

1 reference

12 December 2020

Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions

1 reference

12 December 2020

Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects

1 reference

12 December 2020

Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601218

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520440%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

PubMed publication ID

14520440

1 reference